 SAN DIEGO, Oct. 08, 2021 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. NASDAQ: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the presentation of early clinical data from the NTRK-positive TKI-naïve and TKI-pretreated advanced solid tumor cohorts EXP-5 and EXP-6 of the ongoing TRIDENT-1 Phase 12 study of its lead drug candidate repotrectinib. 